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The nonreceptor protein tyrosine kinase Src plays a crucial role in the signal transduction pathways involved in cell division,
motility, adhesion, and survival in both normal and cancer cells. Although the Src family kinases (SFKs) are activated in various
types of cancers, the exact mechanisms through which they contribute to the progression of individual tumors remain to be
deﬁned. The activation of Src in human cancers may occur through a variety of mechanisms that include domain interaction and
structural remodeling in response to various activators or upstream kinases and phosphatastes. Because of Src’s prominent roles
in invasion and tumor progression, epithelial-to-mesenchymal transition, angiogenesis, and the development of metastasis, Src is
a promising target for cancer therapy. Several small molecule inhibitors of Src are currently being investigated in clinical trials. In
this article, we will summarize the mechanisms regulating Src kinase activity in normal and cancer cells and discuss the status of
Src inhibitor development against various types of cancers.
1.Introduction
Francis Peyton Rous was awarded the Nobel prize in 1966 for
his groundbreaking discovery that a virus could cause cancer
[1]. In 1911, he was able to purify a substance from chickens
that was later shown to be a sarcoma-causing virus (Rous
sarcoma virus). The responsible oncogene was called v-Src
[2, 3]. In 1976, J. M. Bishop and H. E. Varmus discovered
a related gene in chickens, which showed a striking resem-
blance to v-Src. This normal cellular counterpart, cellular
Src (known as c-Src or Src), was the ﬁrst proto-oncogene to
be identiﬁed, and its discovery led to the Nobel prize for
medicine in 1989 [2]. Src was also the ﬁrst gene product
discovered to have intrinsic protein tyrosine kinase activity
[4–6].
Srcbelongstoafamilyof11nonreceptortyrosinekinases
known as the Src family kinases (SFKs); the other ten are
Fyn, Yes, Blk, Yrk, Frk (also known as Rak), Fgr, Hck, Lck,
Srm,andLyn.ThehumangenomecontainsaYespseudogene
(YESps), and Src, Yes, YESps, and Fyn are ubiquitously
e x p r e s s e di nav a r i e t yo ft i s s u e s[ 7, 8]. Srm is found in
keratinocytes, whereas Blk, Fgr, Hck, Lck, and Lyn are
found primarily in hematopoietic cells. Frk occurs chieﬂy
in bladder, breast, brain, colon, and lymphoid cells. Like all
members of the Src kinase family, the Frk kinase possesses
an SH domain as well as conserved autoregulatory tyrosine
residues in its catalytic domain [9, 10]. However, Frk
diﬀers signiﬁcantly from the other Src family members
in many structural features, including the presence of a
putative bipartite nuclear localization signal and the lack of
a consensus myristoylation motif [10, 11]. In fact, Frk has
been shown to be a nuclear protein with growth-inhibitory
eﬀects when ectopically expressed in breast cancer cells [12].
Blk occurs chieﬂy in colon, prostate, and small intestine cells;
however, it was initially isolated from a breast cancer cell line
[13].
In this review, we will discuss the structure of SFKs,
the regulation of their kinase activity, the involvement of
SFKs in the development of cancer, and recent therapeutic
advancements in targeting SFKs.2 Journal of Signal Transduction
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Figure1:SchematicofthestructuraldomainofhumanSrc(Upper)
and v-Src (Lower). The Src molecule is composed of an N-terminal
myristoylation sequence (Myr) attached to the SH4 domain, a
unique region followed by SH3 and SH2 domains, a linker region
(L), a kinase domain (SH1 domain) that contains Tyr419, and
a C-terminal regulatory domain (R) that contains Tyr530. v-Src
protein diﬀers from Src in a number of ways, with one major
diﬀerence being the lack of a regulatory domain (R) at the C-
terminal sequence.
2. Structureof the Src FamilyKinases
The ability of the avian viral oncoproteins v-Src and v-Yes to
induce ﬁbroblast transformation suggests that their cellular
counterparts, Src and c-Yes, have the potential to contribute
to human carcinogenesis. v-Src and v-Yes are encoded by
avian retroviruses and are capable of inducing sarcomas
in chickens and of transforming chicken embryo ﬁbroblast
cells in culture [14, 15]. To understand how these proteins
are able to induce cell transformation, it is important to
understand the functional domain architecture shared by
all SFKs and the role of these domains in both regulating
tyrosine kinase activity and recruiting additional proteins
intosignalingcomplexes.TheseaspectsofSFKbehaviorhave
also been reviewed extensively elsewhere [8, 16].
Src is a 60-KDa protein composed of several functional
domains [13, 17, 18]. Src contains a 14-carbon myristic
acid moiety attached to an SH4 domain, a unique domain,
an SH3 domain followed by an SH2 domain, an SH2-
kinase linker, a protein tyrosine kinase domain (also known
as an SH1 domain), and a C-terminal regulatory segment
[19]( Figure 1). During cotranslational modiﬁcation, the
N-terminal methionine is removed and the resulting N-
terminal glycine is myristoylated by myristoyl-coA. Myris-
toylation facilitates attachment to the inner surface of the
cell membrane [19]. N-myristoylation is required for Src
membrane association and its ability to transform cells
[13, 20]. The diﬀerential state of palmitoylation at the
SH4 domain of SFKs regulates subcellular traﬃcking of
diﬀe r e n tS F K si ni n t a c tc e l l .A l lS F K sa r ec o t r a n s l a t i o n a l l y
myristoylated at Cly2 with the exception of Src and Blk,
which are post translationally palmitoylated at Cys3, Cys5
or Cys6 [21]. Fatty acylation of SFKs has been shown
to regulate their interaction with the cell membrane and
their subcellular distribution [22, 23]. The poorly conserved
unique domain is believed to provide unique functions and
speciﬁcity to each SFK member.
The SH3 domain, composed of ∼60 amino acid residues,
is able to bind proline-rich sequences facilitating SFK-
substrate or intramolecular interactions [19, 24]. The SH2
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Figure 2: Cartoon representation of Src kinase regulation by
diﬀerential phosphorylation at kinase domain as well as C-terminal
regulatory domain.
domain is composed of ∼100 amino acids that can bind
to phosphorylated tyrosine residues on either its own C-
terminal regulatory domain or those of other proteins.
Songyang and Cantley analyzed the binding of a library
of phosphopeptides to the SH2 domain to deﬁne the
preferred docking sequence [25]. The SH2 domain of each
SFK member has distinct peptide preferences towards its
binding partners [26]. The linker domain is involved in
intramolecular binding with the SH3 domain. The catalytic
domain is composed of two subdomains separated by a
catalytic cleft, in which the adenosine-5 -triphosphate (ATP)
and substrate-binding sites reside and phosphate transfer
occurs. The cleft forms an activation loop that contains
Tyrosine 419 (Tyr419; human Src) which is the positive
regulatory site responsible for maximizing kinase activity
[19]. Phosphorylation at the C-terminal end Tyr530 (human
Src), which is a negative regulatory residue, leads to binding
of this region to the SH2 domain; thus a “closed” or
inactive conformation is attained, which is inaccessible to
external ligands. In the closed conformation, the activation
loop attains a compact structure, which ﬁlls the catalytic
cleft and masks Tyr419 residues, thus preventing Tyr419
autophosphorylation and subsequent activation (Figure 2).
3.S r cA c ti vatio ninCanc e r
Src actions on mammalian cells are pleiotropic and include
eﬀects on cell morphology, adhesion, migration, invasion,
proliferation, diﬀerentiation, and survival. Src kinase activa-
tion is common in various types of cancers although acti-
vating mutations and genomic ampliﬁcations are very rare.
Thus, Src activation is usually accomplished by structural
alteration mediated by upstream kinases or phosphatases.
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includeinteractionsthatinﬂuenceitsintramolecularinterac-
tionsandlocalizations.ThenetphosphorylationstatusofSrc
at its regulatory residues determines the activation status of
Src,whichisdependentuponabalancebetweenphosphatase
and kinase enzymes.
3.1. Regulation through the C-Terminal Negative Regulatory
Domain. There are several ways Src kinase activity can be
regulated, and any one of these might contribute to its
activation in cancer cells. These include the phosphorylation
of Tyr530, deletion or mutation of the C-terminal regulatory
region, displacement of the SH3- and SH2 domain mediated
by intramolecular interactions with higher aﬃnity ligands,
and phosphorylation of Tyr419. Independent biochemical
and X-ray crystallographic analyses have revealed that Src
maintains its inactive condition by various internal inter-
actions. The interactions between the SH2 domain and the
C-terminal Tyr530, as well as interactions between the SH3
domain and the SH2-kinase linker, modulate SFK activity
[27].
Phosphorylation of the C-terminal negative regulatory
tyrosine (Tyr530, human Src) is one of the mechanisms for
the regulation of SFK activity. Due to the loss of the C-
terminal residues, the viral proteins v-Src and v-Yes, are no
longer able to be regulated by intramolecular interaction and
become constitutively active and transformation competent
[14, 15]. Regulation through the phosphorylation of Tyr530
in Src is accomplished by several kinases and phosphatases.
Two important protein tyrosine kinases in this process
are Csk (c-Src kinase) and its homolog Csk-homologous
kinase (Chk), which are both able to phosphorylate Tyr530
and to inactivate Src [28–30]. Reduced expression of Csk
might play a role in the activation of Src in some cancers. In
hepatocellular carcinoma, Csk levels are reduced compared
to those in normal liver tissue and this reduced expression
correlates with enhanced Src activity [31]. Evidence suggests
that overexpression of Csk also appears to reduce tumor
metastasis in colon cancer [32]. In addition to the reduced
expression of Csk seen in cancer cells, other modes of
regulating Csk are now being identiﬁed. Csk is structurally
similar to Src, but its mode of regulation is distinct in that it
lacks the regulatory tyrosine residue at the C-terminal end to
control its activity [33].
Another mechanism of the regulation of Csk is through
the transmembrane adaptor protein Cbp (Csk-binding pro-
tein or protein associated with glycosphingolipid-enriched
microdomains [PAG]), a lipid raft-associated binding part-
ner of Csk. Following phosphorylation by Src, Cbp can bind
to the SH2 domain of Csk, thus allowing its recruitment
to the plasma membrane where active Src resides. This
creates a negative regulatory loop in which Cbp mediates
the cross-linking of active Src with its suppressor, Csk
[34]. An independent study by Oneyama et al. showed that
membrane-bound adaptor protein Cbp suppress the Src-
mediated cell transformation and tumorigenesis by binding
and sequestering Src within lipid rafts [35]. Interestingly,
this Cbp-mediated Src suppression was Csk independent.
They have shown that Csk−/− mouse embryonic ﬁbroblast
cells underwent malignant transformation in the presence
of Src [36]. The authors ﬁrst noted that the levels of
endogenous Cbp messenger RNA and protein were reduced
when activated Src was expressed. They then made the
seminal observation that overexpression of exogenous Cbp
reversedtheoncogeniceﬀectofSrc.TheyfoundthatCbpdid
not have any eﬀect on Src tyrosine kinase activity; instead,
it altered Src localization. The SH2 domain of Src binds to
tyrosine phosphorylated Cbp and moves to the raft region
and becomes inaccessible to kinase action. The cytoplasmic
domain of Cbp has two proline-rich SH3 binding motifs
and ten tyrosine residues, nine of which are Src targets.
Oneyama found that phosphorylated Cbp could recruit
SH2 domain-containing proteins such as Csk, SFKs, and
suppressor of cytokine signaling 1 (SOCS1) to lipid rafts
[34]. This ﬁnding further complicated our understanding
of lipid rafts. Previous evidence had suggested that lipid
rafts acted as positive hubs for activated signaling molecules
and their associated SFKs. In order to mediate signals, SFKs
need to be localized to the raft region [37]. Moreover, two
independent studies have shown that SFKs remain active and
can drive cancer cell growth even when bound to lipid-raft
associated Cbps [38, 39]. This conﬂict can be addressed by
studying the diﬀerences in fatty acylation status, cell types,
a n de x t e n to fC b pi n t e r a c t i o nw i t hS F K s .
4. Regulation of Src Activityby Phosphatases
Several protein tyrosine phosphatases (PTPs) are able to
dephosphorylate Src Tyr530 and are responsible for the
regulation of its kinase activity, such as PTPα,P T P γ, SHP-
1 and -2, and PTP1B. PTPα is ubiquitously expressed and
enriched in brain tissue [40–42] and is also able to dephos-
phorylate Tyr419, as evidenced by the lack of pSrcTyr419 in
PTPα-overexpressing cells [40, 43]. Overexpression of PTPα
also can dephosphorylate Src in A431 cell lines and cause
enhancements in cell adhesion [44, 45]. A general question
arises from these studies as to whether PTPα acts as an
activator or repressor of Src molecules. Antisense studies
of PTPα in 3T3-L1 adipocytes [46]a n dP T P α−/− murine
studies [47, 48] show that Src kinase activity is linearly
correlated with levels of PTPα protein in cells.
PTPγ was ﬁrst identiﬁed from chicken brain tissue as
a homolog of CD45 capable of dephosphorylating the SFK
Lck [49]. It is expressed in the spleen and intestine and is
able to dephosphorylate both Tyr530 and Tyr419 residues
in Src. Chappel et al. have shown that PTPγ can modulate
Src activity in osteoclast precursor cells treated with 1,25-
dihydroxyvitamine D3; there was a dramatic increase in Src
kinaseactivitywithoutanincreaseintotalproteinlevels.This
change was accompanied by a decrease in phosphorylation
at Tyr530 Interestingly both PTPγ mRNA and PTPγ protein
levels were upregulated upon 1,25-dihydroxyvitamine D3
treatment suggesting the possibility that PTPg might be
responsible for elevated Src kinase activity [50].
SHP1 is another member of the protein tyrosine phos-
phatase protein family that is also known as PTP-1c. It is
a cytosolic two-SH2 domain containing PTP expressed in4 Journal of Signal Transduction
epithelial and hematopoetic cells [51]. Somani et al. have
shown that SHP1 is responsible for the dephosphorylation
and subsequent activation of Src, and it is much more
speciﬁc for Src Tyr530 than Tyr419. This observation has
been validated in transgenic mice that expressed the mutated
loss of function form of SHP1, which has an increased level
of Tyr530-phosphorylated Src [52].
SHP2 is a cytoplasmic SH2 domain containing PTP,
which is also able to dephosphorylate Tyr530 [53]. SHP2 is
veryspeciﬁcfortheC-terminalregulatorytyrosineresidueof
Src. An independent study by Walter et al. demonstrated that
SHP2 overexpression led to the activation of Src without sig-
niﬁcantchangesintyrosinephosphorylationateitherresidue
(Tyr419 or Tyr530). In addition, the phosphatase-inactive
mutant of SHP2 was also capable of Src activation. Further
studies on the mechanism of Src activation by SHP2 revealed
that the SH2 domain of SHP2 associates with Src by binding
to the Src-SH3 domain and results in the allosteric activation
of Src without involving Src dephosphorylation [54].
Another tyrosine phosphatase known as PTP-1B (also
known as PTPN1) was ﬁrst identiﬁed by Charbonneau et al.
and ﬁrst cloned and puriﬁed from human placenta [55–59].
Later Bjorge et al. demonstrated that PTP-1B was associated
with Src activation in breast cancer cell lines [60]. PTP-1B is
capable of both in vitro and in vivo activation of Src kinase
activity as a result of its speciﬁcity towards tyrosine residues
at the C-terminal tail. Human melanocyte [61] and several
breast cancer cell lines [62] have elevated Src activity with
concomitant hypophosphorylation of Tyr530. Biochemical
analyses showed that these cells have elevated levels of PTP
activity, which correlates with reduced phosphorylation on
the C-terminal residue of Src and may have an important
role in controlling Src kinase activity. The ability of PTP-1B
to modulate Src activity has been demonstrated in mouse L-
cell ﬁbroblasts [63].
Rare activating mutations in Src that are truncated at
codon 531 have been reported in some cases of advanced
colon cancer patients [64]. The Src 531 mutation resulted in
the production of a stop at codon 531, one residue beyond
the regulatory Tyr530. Due to the lack of a C-terminal
regulatory region, phosphorylation of Tyr530 did not result
in a closed conformation and the mutated Src remained
constitutively active.
5. Regulation of Src Activityby Receptor
TyrosineKinases (RTKs)
Src can acts as an upstream or downstream modulator of
several receptor molecules, as well as nonreceptor tyrosine
kinases, which are responsible for the robustness and
persistence of RTK signaling [65] .S r ca c t sa sas i g n a l
transducer from the cell surface receptors by sequential
phosphorylation of tyrosine residues on substrates [66].
Src participates in the activation of various downstream
signaling pathways through molecular interactions with
growth factor receptors such as the epidermal growth factor
receptor (EGFR) family, hepatocyte growth factor receptor
(Met), integrin cell adhesion receptors, steroid hormone
receptors,Gprotein-coupledreceptors,focaladhesionkinase
(FAK) and cytoskeleton components [65, 67]. Src can acti-
vate the phosphatidylinositol 3-kinase (PI3K)-Akt, growth
factor receptor-bound protein 2 (Grb2)-Ras-Raf-mitogen-
activated protein kinase (MAPK), Jak-signal transducers and
activators of transcription (STAT) as well as FAK-paxillin-
p130-Crk-associated substrate (Cas) cascades that are most
crucial for cell cycle progression, survival, and proliferation
[68–72]. Aberrant expression and activation of Src occurs
in several tumor types and has been correlated with poor
clinical outcome, which has stimulated interest in using Src
kinase inhibitors as therapeutic cancer agents, some of which
have entered the clinical trial stage [73, 74].
A variety of Src-binding proteins have been detected
that compete for binding to the protein’s SH domains
and disturb the intramolecular interactions that allow the
activation of Src kinase. v-Src cellular counterpart (c-Src)
forms activated dimerized receptors via its SH2 domain
binding to speciﬁc phosphotyrosine residues in the platelet-
derived growth factor receptor (PDGFR) juxtamembrane
region [75]. Other reports have suggested that activated
PDGFR can phosphorylate tyrosine residues in the SH2/SH3
domain of Src and subsequently activate Src [76–79]. FAK is
another kinase molecule able to bind to the Src-SH2 domain
and activate the kinase activity [80–82]. Additional examples
of regulators are FAK binding partners p130Cas [83, 84]a n d
PTPα [85]. Recently, p130Cas, a protein that is thought to
function as a docking protein because of its large number of
binding motifs, has been demonstrated to bind to Src-SH2
and SH3 domains, resulting in Src activation [84]. Nef [86]
and Sin [87] are examples of proteins that can bind to SH3
domains and activate the Src-family members Hck and Src,
respectively.
There is also evidence to suggest that Src cooperates
with EGFR in growth signaling [88, 89]. Src promotes EGF-
induced anchorage-independent growth and tumorigenesis
in nude mice. Cooperation between these two proteins
depends on Src catalytic activity [90, 91]. EGFR leads to
transient activation of Src kinase activity in glioma cells.
Activation of Src leads to phosphorylation of Tyr845 on
EGFR which is not an autophosphorylation site [92]. In an
independent study on glioblastoma patients, Lu have shown
that Src and Fyn act as eﬀectors of oncogenic EGFR signaling
and enhance invasion and tumor cell survival in vivo.
Selective inhibition of Src and Fyn limited EGFR-dependent
tumor cell motility. Src inhibition combined with an anti-
EGFR monoclonal antibody further inhibited tumor growth
and increased survival in an orthotopic glioblastoma mouser
model [93]. Src is responsible for activation of STAT tran-
scription factors after activation of ErbB1 by EGF, suggesting
thatEGF-inducedmitogenesismightbemediatedbytheSrc-
STAT pathway which is independent of Jak [94]. Recently, we
have shown that Src and c-Met interact diﬀerently in head
and neck cancer cells that are sensitive or resistant to Src
inhibition. Interestingly, however, in both cases c-Met acts as
a direct Src substrate in an in vitro immunocomplex kinase
assay system, which suggests that Src-dependent cell survival
is also regulated by c-Met receptor activation, at least in head
and neck cancer cells [95].Journal of Signal Transduction 5
AnothertierofSrcregulationbyRTKswasdemonstrated
byJiangetal.whoshowedthatEGFR,PDGFR,andﬁbroblast
growth factor receptor (FGFR) phosphorylate Cbp upon
ligand stimulation [96]. The EGFR mediated Cbp phospho-
rylation occurs via Src. Overexpression of Cbp blocks EGFR-
mediated Src activation, signaling, and cell transformation,
whereas loss of Cbp function has the opposite eﬀect. Thus,
Cbp may regulate the synergistic interactions between Src
and EGFR in breast cancer.
6. Focal Adhesion
In a manner similar to many other signaling molecules, Src
exerts its biologic action not only through its enzymatic
activity and multidomain structure but also through its
ability to interact with other signaling molecules in diﬀerent
cellular compartments [97]. Due to its N-terminal fatty
acid moiety, Src associates with the plasma membrane as
well as the perinuclear and endosomal membranes. The
inactive form of Src has juxtanuclear localization. Upon
activation by phosphorylation, Src SH3 domain associates
with actin ﬁlaments, which then drive the translocation of
Src to cell-cell and cell-matrix adhesion sites, where Src can
interact with plasma membrane-bound molecular partners
to take part in two major transduction events. These are
(i) signaling from receptor tyrosine kinases, which mainly
aﬀects cell growth, proliferation, and migration and (ii)
signalingfromadhesionreceptors,includingintegrinsandE-
cadherin, which mainly regulate cytoskeletal functions [98].
Constraints on the SH2 and SH3 domains that are released
whenthemoleculeisactivatedandarealsolikelytoinﬂuence
intracellular signaling by allowing the recruitment of high-
aﬃnity binding partners to speciﬁc intracellular sites. By this
means, conformational activation of Src induces formation
of SH2- and SH3-dependent multiprotein complexes at the
cell periphery.
The primary role of tyrosine phosphorylation is to
generate docking sites for proteins containing SH2 or phos-
photyrosine binding (PTB) domains, thereby promoting
protein-protein interaction and the formation of the macro-
molecular complexes responsible for signal transduction
[99]. Many prominent Src substrates are found in focal
adhesion junctions and include FAK, Cas, and tensins.
Focal adhesion junctions are the sites of integrin-dependent
substrate adhesion.
Tensins are the members of focal adhesion proteins that
can serve as Src substrates. There are four members of the
tensin family in mammals [100]. Tensins 1–3 contain three
distinct regions: the N-terminal domain, which binds to F-
actin and targets molecules for focal adhesion, a noncon-
served centralregion, and the C-terminal SH2- PTBdomain.
The SH2 domains of Tensin-1 are required for promigratory
functions [101], and the SH2 domains of Tensin 2 and 3 are
responsible for binding with proangiogenic tyrosine (Tyr)-
phosphorylated Cas and FAK. Qian et al. showed for the ﬁrst
time that the knockdown of Tensin-3 inhibited Src mediated
cell transformation as well as cell migration and the growth
of cancer cell lines [102].
Previously, Davis et al. showed that Tensin-1 is Tyr phos-
phorylated in Src-transformed chicken embryo ﬁbroblasts
[103]. Qian et al. observed that in a panel of human cancer
cell lines, the level of phospho-Tensin-3 correlated roughly
with both malignancy and with the levels of Src kinase
activity [104]. Furthermore, the level of phospho-Tensin-3
was strongly reduced by speciﬁc inhibition of Src. Tensin-
3 was also phosphorylated at Tyr in a mouse mammary
tumor virus-(MMTV-)polyoma middle T (PyMT) murine
model, in which endogenous Src was activated. This phos-
phorylation was reversed by Src inhibitor PP2. In addition,
recombinant Src was also able to phosphorylate Tensin-3
in vitro [102]. They also have shown that the Tyr residue
of SH2 domain of Tensin-3 at positions 1173/1206 and
1256 was phosphorylated by Src in a range of diﬀerent
types of cancers. Interestingly, Src inhibitors not only
decreased the phosphorylation of Cas and the RNA-binding
protein Sam68, but also decreased its interactions with
Tensin-3.
7.SrcLocalization
Studies on the subcellular localization of Src reveal that
it has been associated with the plasma, perinuclear, and
endosomal membranes [105–109]. Although much evidence
has been acquired regarding the role of Src at the plasma
membrane and its interaction with growth factor recep-
tors and integrin-nucleated focal adhesion complexes for
regulating cell growth and proliferation [8, 66, 97], the
functional signiﬁcance of Src at other subcellular locations,
such as cytoplasmic granules and perinuclear membranes,
has not been as well characterized. The punctate staining
pattern of Src in ﬁbroblasts may represent the protein’s
association with membrane vesicles. Furthermore, analysis
of Src function in Src-overexpressing ﬁbroblasts indicates
a possible association between Src with endosomal mem-
branes [110]. Analysis of indirect immunoﬂuorescence by
three-dimensional optical sectioning microscopy revealed
Src to be associated primarily with membranes at the
microtubuleorganizingcenter,whichrepresentalatestagein
the endocytic pathway [109]. Moreover, Src is also associated
with a number of microtubule-related structures including
microtubulebundlesatpointofcell-cellcontactandaregion
associated with the spindle pole during mitosis that regulates
the transport or function of specialized secretory vesicles
[109].
These data contrast with and extend previous reports of
Src localization at the plasma membrane. One explanation
for this discrepancy was that the biochemical fractionation
techniques used in some prior studies did not diﬀerentiate
between the plasma and endosomal membranes, which have
similar densities and are thus likely to cofractionate [109].
ThepresenceofSrcinsecretoryorganellesofchromaﬃncells
and platelets [111, 112], its association with endosomally
derived synaptic vesicles in diﬀerentiated PC-12 cells [113],
and the development of osteopetrosis in mice that are null
forSrc[114]furthersuggestapossibleroleforSrcinprotein-
traﬃcking events.6 Journal of Signal Transduction
7.1. Perinuclear and Nuclear Signaling. Src exhibits a pre-
dominantly perinuclear pattern of expression in malignant
cells in contrast to a more evenly cytoplasmic distribution
in normal breast epithelial cells [115]. The localization of
Src to perinuclear membranes, endosomes and possibly even
the nucleus suggests that Src is involved in nuclear-signal
transduction events. The tyrosine kinase activity of Src is
increased in mitotic cells arrested with nocodazole [116].
There is growing evidence that Src may play a role in cell
cycle regulation especially at the G1/S transition [117, 118].
A 68kDa phosphorylated protein (Src associated in mitosis,
SAM68) is associated with Src in Src-activated mouse
ﬁbroblasts. An identical 70kDa protein was identiﬁed as a
tyrosine phosphorylated protein that was capable of binding
toLckandregulating T-cellactivation.Ithasbeenpostulated
that Src regulates general splicing and mRNA transport via
its eﬀects on the expression at the posttranscriptional level of
Sam68 [119]. Comparison of several modes of Src activation
demonstrates that Src could either slow down the splicing
rate or allow the export of partially spliced transcript [119].
Overexpression of Fyn in HEK293 cells interferes with the
association of Sam68 with the splicing factor YT521-B and
demonstrates Fyn’s role in mRNA splicing [120]. Gondran
and Dautry further strengthen the importance of Src in
mRNA splicing and transport by inducing mutations at the
SH2andSH3domainsinSrc[121].ThereisevidencethatSrc
can interact with diﬀerent SH2 and SH3 domains containing
signalingmoleculessuchasPLCg-1,Grb2,NCK,Jak3,SHP1,
Cbl, Grap (Grb2 like protein), p21 GTPase, p85 subunit of
PI3K, p47 and Tec kinase family [122–130]. ASAP1, an ADP-
ribosylation factor, is associated with Src [131]. ASAP1 is
found primarily in the cytoplasm in a perinuclear, reticulate
network. The association of Src with ASAP1, Arfs and
PIP2 is thought to be important in coordinating membrane
traﬃcking with actin cytoskeletal remodeling [131, 132]. Src
associates with and phosphorylates various proteins respon-
sible for vesicle transport at the perinuclear region; such
as synapsin, dynamin, and so forth, [133–135]. Golgin67
has also been identiﬁed as a potential Src target, involved
in vesicle docking and tethering [136]. Collectively this
evidence suggests that Src might have a role in membrane
traﬃcking events through transgolgi network [137].
8. Involvement of Src in Human Cancers
Src contribution to cell regulation and cancer development
has been widely discussed in several review articles [74, 97,
138], so the discussion will be limited to a very short sum-
mary of a few relevant concepts and experimental ﬁndings.
T h e r ei sal a r g eb o d yo fe v i d e n c et h a th a sd e m o n s t r a t e d
that Src kinase activity and protein levels are elevated in
several cancers, including those of the colon and breast.
A correlation has often been observed between increases
in Src kinase activity and the progression of malignancy
[62, 64, 97, 115, 139–141]. Previously, we showed that Src
promotes cancer cell survival in conjunction with STAT3 in
head and neck squamous cell carcinoma (HNSCC) and non-
small cell lung carcinoma (NSCLC) cells [142, 143].
Recently, Zhang et al. provided both clinical and experi-
mental evidence that Src plays a critical role in the establish-
ment of latent bone metastasis in breast cancer [144]. Using
a bioinformatic approach that investigated the association
between various signaling pathway-speciﬁc gene expression
patterns and breast cancer, they identiﬁed a “Src activity
gene expression signature” (Src responsive signature, SRS)
that was highly associated with late onset of bone metastasis
in breast cancer. To address the role of Src in the process
of bone metastasis, they used two SRS-expressing breast
cancer cell lines that possessed either aggressive or indolent
metastatic bone tropism in a xenograft mouse model. In
the cell line possessing aggressive metastatic bone tropism,
stable knockdown of Src resulted in a signiﬁcantly decreased
rate of tumor outgrowth of bone lesions. In an indolent
model of bone metastasis, knockdown of Src led to complete
loss of bone metastatic activity, whereas the silencing of Src
did not alter lung or lymph node metastatic activity, thus
supporting a speciﬁc role for Src in bone metastasis. These
prominentﬁndingssetthestageforthedevelopmentofnovel
therapeuticstrategiesforeradicatingbreastcancermetastasis
to bone.
In 2009, Yim et al. showed that the ectopic expression of
Rak (also known as Frk) eﬀectively suppressed breast cancer
cell proliferation, invasion, and colony formation in vitro
and tumor growth in vivo via its regulation of PTEN protein
stability and function. Thus Rak may function as a tumor
suppressor gene. Further understanding of its function may
contribute to eﬀective therapeutic approaches for both Rak-
and PTEN-defective cancers [145].
Using integrated genomic and phosphoproteomic analy-
sis of mouse lung primary and metastatic tumors, Carretero
et al. demonstrated that loss of tumor suppressor LKB1
led to the activation of Src and FAK in a KrasG12D/Lkb1
murine model of lung tumor [146]. Src and FAK activation
result in focal adhesion disassembly and turnover through
the downregulation of Ras homolog gene family, member
A (RhoA), which results in an increase in cellular motility
and migration in the process of metastasis. They also
conﬁrmed the involvement of Src in the regulation of
metastasis in KrasG12D/Lkb1 lung tumors by inhibiting Src,
withconcomitantincreaseinthesensitivityoftumortowards
PI3K-MEK inhibition.
9. ClinicalTrialsof Src Inhibitors
A large body of evidence, including that discussed above, has
identiﬁedSrcasakeymoleculeintumorprogressionthatcan
provide oncogenic signals for cell survival, EMT, mitogene-
sis, and invasion and angiogenesis and metastasis [74, 147].
Due to the positive correlation between the development of
cancer and the upregulation of Src activity, Src is emerging
as a promising target for anticancer therapy [148, 149]. Src
inhibition also results in a reduction of cancer progression
in several cancer types [150–152], thus suggesting a potential
clinical usefulness to inhibiting Src. There are several small
molecule inhibitors for Src kinase that are undergoing
clinical trials after promishing preclinical studies, such as theJournal of Signal Transduction 7
Table 1: Src inhibitors with other agents in clinical trials.
Drug Phase Tumor type Combination agent
Dasatinib
II Advanced-NSCLC/Colorectal/Pancreatic/HNSCC/Breast/SCLC/Melanoma —
II Resectable NSCLC/HNSCC Erlotinib
I-II Advanced NSCLC Erlotinib
I Breast Capecitabine
I Breast Paclitaxel
I-II Prostate/castration resistant prostate cancer Docetaxel
I Colon FOLFOX6/Cetuximab
Saracatinib
II Prostate/Pancreatic/Osteosarcoma/Soft tissue sarcoma/Melanoma/Gastration-resistant
prostate cancer/Thymoma/Colorectal/HNSCC
—
II Advanced NSCLC/SCLC Carboplatin/Paclitaxel
I Advanced solid tumor Cediranib
I-II Pancreatic Gemcitabine
II Ovarian Carboplatin
II Prostate/Breast with bone metastasis Zoledronic acid
Bosutinib
II Breast —
II Breast Exemestane
II Breast Letrozole/Capecitabine
I-II Advanced solid tumor Capecitabine
XL228 I Advanced solid tumor —
KX2-391 I Advanced solid tumor/Lymphoma —
AZM475271 I-II Pancreatic —
XL999 I Advanced solid tumor —
ATP-binding competitive inhibitors dasatinib (BMS-354825,
Sprycel), bosutinib (SKI-606), saracatinib (AZD530), pona-
tinib (AP24534), bafetinib (INNO-406), and the substrate
binding-site inhibitor Kxo-I (KX2-391) [153–157]. Pre-
liminary data suggest that the agents are well tolerated
at doses that achieve clinically meaningful plasma drug
concentrations. Recent clinical studies with Src inhibitors as
single agents or in combination are shown in Table 1.
Dasatinib suppressed invasion and induced cell cycle
arrestinHNSCCcellsinvitro[158],aﬀectedthemechanisms
of prostate tumor progression [159], and greatly inhibited
the development of liver metastasis in an orthotopic murine
model of pancreatic carcinoma. Studies of dasatinib in
prostate [160] and colon cancer cell lines [161] showed inhi-
bition of cellular adhesion, migration, and invasion. Breast
cancer cell lines belonging to the basal/“triple-negative” sub-
type were particularly sensitive to dasatinib. Breast cancers
within this subgroup express basal cell cytokeratins (CK5
and CK17), with ER, PR and Her2 negative phenotype
[162, 163], and are well known for poor prognosis [164].
Interestingly,inEGFR-overexpressingbreastcancercelllines,
dasatinib inhibited cell growth, invasion, and angiogenesis,
and stimulated apoptosis by activating caspase 8 and 9 [165].
Bosutinib showed activity against colon cancer in a
murine model and was well tolerated. In cellular assays,
bosutinib treatment resulted in a dose-dependent reduction
in proliferation, invasion, and migration of breast cancer
cells [166, 167]. Furthermore, in a murine model of
breast carcinoma, bosutinib inhibited tumor growth and
signiﬁcantly reduced the number of liver, spleen, and lung
metastases. Clinical trials with bosutinib for breast cancer,
other solid tumors, and leukemia are ongoing [168].
Saracatinib (formerly AZD0530; AstraZeneca) is another
ATP-competitive inhibitor of SFKs, with activity against ABL
and activated mutant forms of EGFR (L858R and L861Q)
[169]. In a panel of 13 human cancer cell lines treated with
saracatinib, there was growth inhibition in four diﬀerent cell
lines (derived from colon, prostate, and lung tumors) and
inhibitory eﬀects on migration and invasion [170, 171].
In a recent phase II trial with dasatinib as a ﬁrst line
of treatment for metastatic NSCLC several patients had
prolongedstablediseaseandonepatienthadanearcomplete
response that persisted 2 years after the start of therapy, sug-
gesting that there was a subset of patients with NSCLC who
beneﬁted from Src inhibition [172]. Another independent
phase I/II study in NSCLC using the combination of Src
and EGFR inhibitors also demonstrated clinical responses
[173,174].Theseobservationsfurthervalidatethepreclinical
ﬁndings that suggest there is cooperation between EGFR
kinase activity and Src in NSCLC [158, 175–177].8 Journal of Signal Transduction
In a phase II trial in 2008, Yu et al. demonstrated that
dasatinib improves the overall survival in castration resistant
prostatecancer[178].Basedonpromisingresultsfromphase
I/II clinical trials of combination treatment with dasatinib
and docetaxel in prostate cancer patients, this combination
is now being tested in a phase III clinical trials [118, 119].
M475271isanoralinhibitorofSrcandvascularendothe-
lial growth factor receptor (VEGFR) that has shown preclini-
cal activity in lung adenocarcinoma cell lines [179]. Another
SFK inhibitor, KX2-391, targets the peptide substrate-
binding site rather than the ATP-binding site. Based on
the promising results from phase I study, a phase II study
has been initiated with Castration-Resistant Prostate Can-
cer Bone-Metastatic patients [180], (http://www.clinicaltrial
.gov/).Allthesetherapeuticagentsappeartobewelltolerated
and we eagerly await their detailed clinical results.
10. Conclusions
Our understanding of Src structure and function, regulation,
and localization has increased dramatically since its discov-
ery. One-hundred years after the original description of Src,
this protein continues to attract keen interest because of its
multiplicity of actions in the molecular signaling pathways
underlying developmental as well as oncogenic events. Many
studies have addressed the molecular mechanisms of Src
regulation in cells and tumor tissues. In order to clarify and
fully elucidate the normal physiologic function of Src and
other SFKs and to fully comprehend Src signaling networks
in various cancers, Src interactions with speciﬁc targets or
binding partners in diﬀerent subcellular localization studies
should be characterized in as much detail as possible.
Special focus should be placed on the role of Src in
bone metastasis because of the protein’s role in osteoclast
and osteoblast function. Moreover, preclinical reports of
combination treatments involving chemotherapy, radiation
therapy, and targeted therapies with a Src inhibitor warrant
further investigation [181, 182].
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